<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607825</url>
  </required_header>
  <id_info>
    <org_study_id>R1.0 11July18</org_study_id>
    <nct_id>NCT03607825</nct_id>
  </id_info>
  <brief_title>FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension</brief_title>
  <acronym>PILLAR-XT</acronym>
  <official_title>ExtracorPoreal FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR EXTension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minnetronix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minnetronix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to further demonstrate safety and characterize effectiveness&#xD;
      of the Neurapheresis™ System (extracorporeal system and catheter) to remove red blood cells&#xD;
      (RBCs) and lysed blood by-products from hemorrhagic cerebrospinal fluid (CSF) following&#xD;
      aneurysmal subarachnoid hemorrhage (aSAH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PILLAR-XT study is designed to further confirm safety and characterize efficacy of&#xD;
      Neurapheresis therapy. The study works in tandem with the current SOC treatments for SAH and&#xD;
      does not detract from the established care pathways, or deny enrolled subjects proven&#xD;
      therapies. The PILLAR-XT study utilizes the established skill sets of chosen Investigators&#xD;
      who are already trained in the treatment and care of SAH patients and insertion/management of&#xD;
      lumbar drains.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 25, 2018</start_date>
  <completion_date type="Actual">February 17, 2021</completion_date>
  <primary_completion_date type="Actual">January 11, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Cisternal Blood</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>Documented by CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Red Blood Cells</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>CSF analysis of RBCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Total Protein</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>CSF analysis of Total Protein</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Neurapheresis System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSF filtration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurapheresis System</intervention_name>
    <description>CSF filtration system and lumbar catheter</description>
    <arm_group_label>Neurapheresis System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Modified Fisher Grade 2, 3 or 4&#xD;
&#xD;
          -  Hunt &amp; Hess I-IV&#xD;
&#xD;
          -  First aneurysmal SAH&#xD;
&#xD;
          -  Patient is ≤ 48 hours post bleeding event&#xD;
&#xD;
          -  World Federation of Neurosurgeons (WFNS) Grades I-IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with a SAH due to mycotic aneurysm or AV malformation&#xD;
&#xD;
          -  Patients who present with an acute MI or unstable angina&#xD;
&#xD;
          -  Imaging demonstrates supratentorial mass lesions &gt; or = 15 cc&#xD;
&#xD;
          -  Imaging demonstrates &gt; or = 2 mm of mid-line-shift associated with infarction and or&#xD;
             edema&#xD;
&#xD;
          -  Effacement of the basilar cisterns&#xD;
&#xD;
          -  Vasospasm on admission as defined by angiographic evidence&#xD;
&#xD;
          -  Patients with a coagulopathy that cannot be reversed&#xD;
&#xD;
          -  Thrombocytopenia def. platelet count &lt; 100,000&#xD;
&#xD;
          -  Patients on low molecular weight heparin such as Lovenox&#xD;
&#xD;
          -  Non-communicating Obstructive hydrocephalus&#xD;
&#xD;
          -  Existing hardware that prevents accurate CT imaging&#xD;
&#xD;
          -  Pre-existing Lumbar Drain&#xD;
&#xD;
          -  Local skin infections or eruptions over the puncture site&#xD;
&#xD;
          -  Signs of CNS systemic infection, sepsis or pneumonia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aneurysmal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

